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Scientists have injected endotoxin into animals to investigate and understand various pathologies and novel
therapies for several decades. Recent observations have shown that there is selective susceptibility to Escherichia
coli lipopolysaccharide (LPS) endotoxin in sheep, despite having similar breed characteristics. The reason behind this
difference is unknown, and has prompted studies aiming to explain the variation by proteogenomic
characterisation of circulating acute phase biomarkers. It is hypothesised that genetic trait, biochemical,
immunological and inflammation marker patterns contribute in defining and predicting mammalian response to
LPS. This review discusses the effects of endotoxin and host responses, genetic basis of innate defences, activation
of the acute phase response (APR) following experimental LPS challenge, and the current approaches employed in
detecting novel biomarkers including acute phase proteins (APP) and micro-ribonucleic acids (miRNAs) in serum or
plasma. miRNAs are novel targets for elucidating molecular mechanisms of disease because of their differential
expression during pathological, and in healthy states. Changes in miRNA profiles during a disease challenge may be
reflected in plasma. Studies show that gel-based two-dimensional electrophoresis (2-DE) coupled with either
matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) or liquid
chromatography–mass spectrometry (LC-MS/MS) are currently the most used methods for proteome
characterisation. Further evidence suggests that proteomic investigations are preferentially shifting from 2-DE to
non-gel based LC-MS/MS coupled with data extraction by sequential window acquisition of all theoretical
fragment-ion spectra (SWATH) approaches that are able to identify a wider range of proteins. Enzyme-linked
immunosorbent assay (ELISA), quantitative real-time polymerase chain reaction (qRT-PCR), and most recently
proteomic methods have been used to quantify low abundance proteins such as cytokines. qRT-PCR and next
generation sequencing (NGS) are used for the characterisation of miRNA. Proteogenomic approaches for detecting
APP and novel miRNA profiling are essential in understanding the selective resistance to endotoxin in sheep. The
results of these methods could help in understanding similar pathology in humans. It might also be helpful in the
development of physiological and diagnostic screening assays for determining experimental inclusion and
endpoints, and in clinical trials in future.
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During subsequent studies based on an ovine model of
transfusion-related acute lung injury [1-3], unpublished
observations showed that some sheep were more suscep-
tible to the effects of Escherichia coli lipopolysaccharide
(LPS) endotoxin than others from the same mob. Endo-
toxin LPS from E. coli serotype O55:B5 was infused into
sheep to prime their immune system without causing
LPS-induced acute lung injury. As a result, the more
susceptible sheep required considerably less LPS to
prime their immune system. It is not known why this
observation occurred, despite the sheep being the same
breed, with similar characteristics. This striking observa-
tion of differential susceptibility to LPS has prompted
studies that seek to explain the variation. It has recently
been proposed that tolerance to endotoxin is one mech-
anism among others involving reprogramming of im-
mune system cells to regulate inflammation and protect
the host against shock [4]. Sheep play a vital role when
used as large animal models in understanding human
disease [5]. To date, however, data on the use of sheep is
scarce and yet these production animals fulfil the criteria
in the quest for clinically relevant large animal models
that can generate robust mechanistic information that
lends itself to translational research. Current evidence
from landmark genomic studies points out that mouse
models that have traditionally been used in research are
remote from human conditions [6], which underscores
the relevance of sheep. Recent advances in the mapping
of the sheep genome and breed variation [7] may help to
further elucidate genetic and phenotypic differences seen
during natural and experimental disease challenges. We
have formulated the hypothesis that the genetic trait,
biochemical, immunological and inflammation marker
patterns of the host contribute in defining and predict-
ing the response to the bacterial endotoxin (LPS)
challenge.
The focus of the current review is on the proteoge-
nomic approaches of studying circulating acute phase
biomarkers that could help to explain selective suscepti-
bility to endotoxin in sheep. On the same theme, the ef-
fects of endotoxin in animals and understanding of
immunity and infection are outlined. The genetic basis
of innate defences, the activation of the acute phase re-
sponse (APR), and the different methodologies employed
in detecting novel biomarkers specifically acute phase
proteins (APP) and microRNAs (miRNAs) in serum or
plasma are discussed. Acute phase proteins are noted as
excellent candidates to study in animal models of disease
[8]. The inclusion of circulating miRNAs is a novel ap-
proach as they have been proposed to play a key role in
the modulation of endotoxin tolerance as reviewed re-
cently [4]. The methodologies discussed include routine
haematology and biochemistry panels, contemporaryproteomic and high throughput genomic approaches.
With omics (branch of study in life sciences with the suf-
fix -omics, such as genomics, proteomics [9,10])
methods, it can be advanced that it will be feasible to
understand the molecular mechanisms and gene expres-
sion traits responsible for the selective susceptibility to
endotoxin and disease challenge in sheep. An under-
standing of associated markers of the selective morbidity
of sheep to endotoxin may help to understand or predict
similar pathology in humans. Furthermore, this know-
ledge could be used in developing strategic bioassays for
use in physiological screening of animals prior to recruit-
ment in experimental studies, and, most importantly, for
improving animal welfare and production.
A - Endotoxin: the molecular trigger of the immune
system
An endotoxin is a bacterial toxin that is integral and
major part of the cell wall of Gram-negative (G-ve) bac-
teria. It is made of lipopolysaccharides (LPS), which are
biologically-active molecules that bind either directly to
the plasma membrane of mammalian cells, or complex
with LPS-binding protein (LBP) prior to endocytosis
[11,12]. LPS are localised in the outer layer of the
membrane and in non-capsulated bacteria, it is exposed
on the cell surface [12]. In G-ve bacteria, the lipo-
polysaccharide membrane protects the bacterium against
the action of lipophilic antibiotics [12] and detergents.
Bacterial endotoxins are considered to cause the most
pathophysiological reactions during infection [13]. LPS
endotoxins are key factors in septic shock in humans
[14,15], induce strong immune responses in normal
mammalian cells [12,16] and are known to be an im-
portant cause of acute respiratory distress syndrome in
both humans and animals [17]. The lipid A component
of LPS is primarily responsible for immune response ac-
tivation [18]. When G-ve bacteria cells are lysed by the
immune system, particles of the membrane containing
lipid A are released into the systemic circulation, leading
to fever, sometimes diarrhoea, and endotoxic shock or
sepsis with potentially fatal consequences [14,15,18,19].
How do mammalian hosts respond to endotoxin? LPS
constitute microbial structures called pathogen associ-
ated molecular patterns (PAMPs) that are recognised by
blood- and cell-associated protein triggering inflamma-
tion [20] through a precise sequence [21]. The innate in-
flammatory response to LPS is mediated via toll-like
receptors 4 (TLR4) [4,16,22]. In circulation, LPS is iden-
tified and bound by LBP which delivers LPS to the
membrane-bound receptor called cluster of differenti-
ation 14 (CD14), creating CD14/TLR4/LBP complex
[19,23]. When engaged by LPS, as in Gram-negative in-
fection, this complex (CD14/TLR4/LBP) transduces a
signal detected by the myeloid differentiation primary
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cade of the interleukin-1 receptor-associated kinases
(IRAKs), tumour necrosis factor receptor associated
factor 6 (TRAF6), and nuclear factor (NF)-kappaB indu-
cing kinase (NIK), resulting in activation of NF-kappaB
[4,23]. This promotes the secretion of pro-inflammatory
cytokines including interleukin 6 (IL-6), tumour necrosis
factor-α (TNF- α) and interleukin-1β (IL-1β) [12,21,24].
Cytokines are target genes of LPS signalling and are acti-
vated or downregulated via these transcription factors
[16]. The production of pro-inflammatory cytokines and
chemokines then finely regulates the systemic reaction
events [21]. Readers are referred elsewhere [25-27] for de-
tailed schematic illustrations of TLR4 pathway signalling.
Lipopolysaccharide preparations continue to be the
mainstay of experimental models of infection, but why
only in small animals? The good news is that studies are
starting to emerge that have used large animals in re-
search for the elucidation of LPS immunology [28],
blood transfusion studies [2,3], physiology and many
other processes to induce synthesis and secretion of
intermediary factors such as interleukins [12,29], and in
the study of acute phase response [13] in animals. In the
quest to characterise the acute phase response, Kabaroff
et al. [19] challenged ewes with a range of doses of
E. coli endotoxin. Their study observed that the expres-
sion of TLR4, CD14, IL-6, TNF- α, IL-1β, macrophage
migration inhibitory factor, 11-β-hydroxysteroid de-
hydrogenase and tachynin precursor 1 hepatic genes was
dependent on both the dose and the kinetics of the re-
sponse to LPS [19]. It would have been interesting to de-
termine if there were any soluble gene expression
transcripts in plasma and serum. In mice, for instance, it
has been shown that the key factors responsible for the
sensitivity to endotoxin infusion are found in serum, not
the host cells [30]. This information is lacking in sheep,
therefore warranting investigation. The identification
and harnessing of these circulating factors may help to
develop strategies that can dampen response to bacterial
diseases [31] in sheep. Whilst there is still debate as to
whether animal models of endotoxaemia are relevant to
human sepsis, as reviewed by Seok et al. [6], Ward [20]
and Munford [31], the use of LPS to simulate infection
by priming the immune system of the host and to meas-
ure immunological and markers of inflammation in
serum of sheep will undoubtedly open doors to this un-
explored area of data-scarce large animal species. It has
been documented that animals that survive an exposure
to endotoxin or Gram-negative bacteria often develop
tolerance to subsequent challenges with LPS [31]. This
may, in part, help to explain why there is differential re-
silience to the effects of endotoxin in addition to im-
munity and genetics of the individual – which is the
premise for this review.B - Infection, immunity and the role of genetics
The fundamental definition of disease resistance in-
cludes freedom from clinical signs of disease after chal-
lenge [32]. Animals resist infection by way of innate and
adaptive immunity strategies. Innate immunity involves
physical barriers like the skin, innate immune cells such
as dendritic cells, monocytes, natural killer cells, lym-
phocytes and inflammatory cytokines [8,33]. The injec-
tion of an endotoxin intravenously may therefore not
simulate what happens in natural infections as this
avoids the acute phase of infection [31] and traverses
some of the innate immunity barriers. It is well recog-
nised that a heightened tolerance to pathogens is an im-
portant selection objective in most livestock species.
Also, animals that survive an exposure to endotoxin or
Gram-negative bacterial infection often develop to-
lerance to subsequent challenges with LPS and other
microbial agonists [31]. This is by way of adaptive im-
munity which is antigen-specific and requires the recog-
nition of specific antigens via a process of antigen
presentation that results in an immunological memory
[31,33].
Studies have also shown that various innate and adap-
tive immune traits are genetically controlled, and resist-
ance to disease is an evolutionary trait responsible for
survival [33]. Most work on sheep has shown that vari-
ation in resistance to internal parasites, fleece rot, fly
strike, and dermatophilosis is genetically determined
[32]. In animal production, the relative importance of
infectious diseases depends on their impact on welfare
and production; genetic approaches to disease control
have only been considered where conventional control
measures have been ineffective [32], which leaves con-
siderable knowledge gaps in this field. Along this line,
Albers et al. [34], have been able to recognise and esti-
mate genetic relationships among resistance and resili-
ence to internal parasite burdens as being important
production characters in sheep. Their study deduced
that realistic additions to existing selection criteria for
Merino sheep should include productivity when in-
fected, and resistance to infestation [34]. Furthermore,
the potentially negative impact of reduced selection ef-
ficiency on production traits has also been observed in
sheep in some reports [32]. This could be elucidated by
understanding the mechanisms underpinning the resist-
ance, the intricate genes and the use of biomarker-
assisted selection [32]. In other species like wild rodents,
for example, phenotypic variation in immune function
and pathogen resistance has been shown to occur in
natural populations [35,36], which strengthens the no-
tion that there is a genetic basis to this variation. In
summary, infection, the immune system and the genetic
factors all interact to mount an acute phase response
(APR).
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signaling
The physiological response to infection and injury
involves inflammation, in the first instance, leading to
the activation of the body’s immune system-mediated
defence mechanisms, collectively referred to as APR
[21,37-39]. The APR is an innate, non-specific reaction
which occurs in animals shortly after an infection,
inflammation, trauma, surgery neoplasia or immuno-
logical disorders prior to specific immunity development
[39,40]. Innate immunity therefore fulfils an important
role in the body’s early defence by initiating APR that
triggers the production of blood acute phase proteins
(APP) mainly by hepatocytes [8]. The production of APP
is regulated by specific genes [41]. Other than hepato-
cytes, several other tissues and cell types are known to
make APP as well [21]. APR is a multifaceted systemic
primary defence system activated by trauma, infection,
stress, neoplastic processes and inflammation [8,21]. The
APR is a core part of the innate immune response and is
observed across all animal species [8,38]. The APR is
mediated mainly by pro-inflammatory cytokines [40],
acting as messengers between the local site of injury and
the cells that synthesise APP [38]. As far as disease re-
sistance in sheep is concerned, Raadsama et al. [32]
asserted that genetic variations exist in acute phase re-
sponses in almost every case that has been investigated.
Therefore, continuous focus on alternative selection cri-
teria including biomarkers such as DNA [32], APP and
miRNA are warranted. The latter two novel additions
and products of the APR have a tremendous potential
as biomarkers to enhance the understanding of host-
pathogen relationships and provide new avenues for de-
veloping tools for mitigating the effects of disease.
D - Biomarkers: the pathognomonic yardsticks for
biological processes
A biomarker is an objective, quantifiable characteristic of a
biological process [42]. Biomarkers include established
measurable physiological parameters like body temperature,
heart rate, respiratory rate (the TPR adage), haematological
& biochemical parameters, acute phase proteins, and gene
expression transcripts like cytokines and novel miRNAs all
of which are necessary for investigations of the systemic im-
pact of disease. The effects of disease cause physiological
derangements that can be measured by haemodynamic,
respiratory and temperature monitoring technology. De-
tailed insights on the practices of haemodynamic moni-
toring practices are beyond the scope of this review and
can be found elsewhere [43-48]. Respiratory monitoring
is not only about checking if the chest is moving; it
is more about the analysis of actual pulmonary gas
exchange. Gas exchange can be quantified by pulse
oximetry which provides a measure of oxyhaemoglobinsaturation in blood and is one of the most useful param-
eters [49-52] in addition to the measurement of end tidal
carbon dioxide tension. Blood gas analysis provides infor-
mation on partial pressures of O2 and carbon dioxide.
Absolute values for oximetry including the concentrations
of total blood haemoglobin, oxygen saturation, fractions of
oxyhaemoglobin, methaemoglobin, carboxyhaemoglobin,
and de-oxyhaemoglobin are also attainable by blood gas
analysis. Modern blood analysers also provide measure-
ments for blood acid-base status, electrolytes and metabo-
lites. Complete blood cell counts including platelets,
differential white cell counts and serum or plasma bio-
chemical analysis [53] continue to be the mainstay of rou-
tine biomarker benchmarks of organ function in practice.
Acute phase proteins
APP are large structurally unrelated proteins [21] that
are considered biomarkers, and their assay can provide
an evaluation of the activating event [8,54-56]. It is also
known that APP are sensitive markers of infection and
inflammation in animals [8,38]. Later in APR, innate re-
sponses are reliant on cytokines and chemokines which
are generated by activated cells including fibroblasts,
macrophages, platelets, monocytes, endothelium, kerati-
nocytes and T-cells [8].
The fundamental objective of studying APP is to
understand the pathophysiology of disease processes
involved during innate immune response to infections
in order to improve the welfare of animals [21]. Their
characterisation has potential in medical interventions
and in monitoring disease processes. It has been pro-
posed that, as in humans, the monitoring of systemic
inflammation in veterinary patients could be achieved
by the determination of APP profiles [57]. The latter
may in fact be useful in monitoring the health status
of animals during farm production, slaughter [40,58]
and agistment in the case of experimental animals, as
well as monitoring their health status. Cross-species
comparisons have indicated a considerably high degree
of similarity in the patterns of APR [39]; however, al-
though APR is highly conserved in nature, APP pro-
files show a significant variability between species [59].
In other words the relative level or magnitude of ex-
pression of different APP varies depending on the spe-
cies. It has been established that APR leads to fever,
leucocytosis, significant alterations of APP in plasma
or serum [21,38] and increased numbers of circulating
neutrophils and their precursors [38].
More than 200 APP have been recognised and are
grouped as either positive or negative, contingent on
whether they increase or decrease, respectively during
APR [8,21,38]. Albumin is the major negative APP that
decreases in nearly all animal species during APR
[8,21,38]. The downregulation of hepatic synthesis of
Table 1 Biologic functions of some common acute phase
proteins (APP)
Acute phase protein Function
C-Reactive protein (CRP) Opsonises infectious agents to activate
complement and phagocytosis. Up- or
downregulates cytokine production and
chemotaxis. Has both pro-inflammatory and
anti-inflammatory effects.
Serum amyloid P Analogue of CRP in some animals.
Serum amyloid A (SAA) Chemotaxis of polymorphonuclear cells,
monocytes, and T cells. Downregulates the
inflammatory process. Binds cholesterol
and modulates innate immune reactions.
Known as an innate immunity opsonin.
Albumin Binds fatty acid, bilirubin. Regulates
osmotic pressure.
Haptoglobin (Hp) Dampens oxidative damage due to
haemolysis by binding free haemoglobin.
Bacteriostatic. Immunomodulator.
Angiogenesis and chaperone activity.
α1-Acid glycoprotein (AGP) Binds and inhibits LPS. Downregulates
neutrophils and complement. Transports
molecules in plasma. Immunomodulator of
white blood cells. Reduces apoptosis of
bovine monocytes. Antibacterial.
α1-macroglobulin Protease inhibitor; removes enzymes
released during injury.
Lipopolysaccharide binding
protein (LBP)
Binds LPS, activates innate immunity.
Modulates biological activity of immune
cells. Opsonin.
Inter α trypsin inhibitor
H4 (ITIH4)
Protease inhibitor.
Fetuin (α HS glycoprotein) Bone growth, foetal development
α1 Anti proteinase
(Anti trypsin)
Protease inhibitor
Major acute phase protein
(Porcine) (pig-MAP)
Trypsin inhibitor (porcine species).
Ceruloplasmin Scavenges free radicals.
Paraoxanase Oxidase inhibitor.
Lipoprotein Lipid transport.
Retinal binding protein Transport of vitamin A.
Mammary-associated
serum amyloid A3
Milk APP.
Fibrinogen Precursor for fibrin, tissue repair.
Transferrin Positive APP in avian species and negative
in mammals. Immunomodulator, protein
transport, tissue protection from damage
from inflammation.
Table reflects information from references [8,21,37,38].
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be available for gluconeogenesis [21]. Positive APP are
those that increase during APR and can be further cate-
gorised as major, moderate or minor depending on the
degree of increase during APR [8]. There are species dif-
ferences in the classification of positive APP [38]. In
sheep, for example, the major APP (>10-fold increase)
are haptoglobin and serum amyloid A, while α1-acid
glycoprotein (AGP) and C-reactive protein are moderate
APP (1- to 10-fold increase) [8]. In humans, C-reactive
protein (CRP), the APP of main interest, and serum
amyloid A are major APP, while AGP, fibrinogen and
haptoglobin are moderate APP [8]. Serum amyloid A is
consistently a major APP in the cat, ox, dog, goat, horse,
man, mouse, pig, and rabbit, but not in the chicken,
non-human primates and rat [8]. As an example from
another species, Orro et al. [13] demonstrated that chal-
lenge with E. coli endotoxin in reindeer can activate
APR, and serum amyloid A appears to be a more sensi-
tive indicator of APR than haptoglobin in this species
[13]. It is known that different pathophysiological chal-
lenges generate different patterns of APP; therefore, not
all of them change uniformly in all diseases or in each
animal [21]. A wider application of APP in veterinary
medicine has only heightened in the last decade [8] and
a lot remains to be learned. The biologic functions of
some common APP are presented in Table 1.
An extensive summary of the triggering event and the
significant changes in APP in animals has been reviewed
by Cray et al. [8]. Their review noted that the uses of
APP assays are well supported in the human and veter-
inary studies with many potential uses in laboratory ani-
mal medicine [8]. Specific reports on APP alterations in
sheep have been published, for instance during bacterial
infections [60-62], yeast infection [63] and in an experi-
mental model of bacterial lymphadenitis [64]. In one
study, it was noted that ceruloplasmin, fibrinogen and
haptoglobin increased and albumin decreased during a
yeast infection [63]. Sheep with rhino-tracheo-bronchitis
show significant decreases in transthyretin, apolipopro-
tein A1, and increases in haptoglobin, endopin 1b and
alpha 1β- glycoprotein [62]. In cattle, serum haptoglobin
concentration is useful in the effective diagnosis and
prognosis of enteritis, peritonitis, pneumonia and endo-
carditis [21]. Research shows that sheep and goats have
similar APP responses as cattle [21], but this could still
be an assumption. In sheep, AGP shows a moderate, but
extended, response after an inflammatory stimulus, sug-
gesting that it is a marker for chronic conditions in this
species [64] and goats [65]. Fibrinogen is a moderate
APP in small ruminants [65]. It is important that these
findings are replicated in order to formulate a standard.
The APP have been reported to be more sensitive than
complete blood count analysis as makers of infectionparticularly in sheep [60]. For example, APP assay can
differentiate between acute and chronic states of infec-
tious conditions such as caseous lymphadenitis [64]. In
Merino lambs, APP assays have been shown to be useful
in evaluating the systemic effects of different procedures
for controlling breech flystrike [53,66,67]. This can po-
tentially help to identify the procedures associated with
Table 2 Families of some known cytokines
Family Members Action
TNF 20 Pro-inflammatory
IL-1 11 Members including
IL-1α, IL-1β, IL-18 and IL-33
Pro-inflammatory
IL-6 IL6, Leukaemia inhibitory
factor, IL-11, oncostatin,
ciliary neuroptic factor
and cardiotropin-1
Acute phase response,
Pro-inflammatory, diverse
biological activities
IL-10 IL-10, IL-22 Anti-inflammatory
Colony
stimulating
factors (CSF)
IL-3, granulocyte-CSF,
granulocyte-macrophage
CSF, macrophage CSF
Overlapping functions,
distinct gene products,
and have specific receptors.
Chemokine CXCL8 (formally known
as IL-8)
Chemotactic
Interferons IL-2, IL-4, IL-7, IL-9, IL-15,
and IL-21
Antiviral, modulate
several immune
responses, share a
common receptor chain,
exclusively produced by
activated T Cells.
Table reflects information drawn from references [38,71,73].
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can be used as a prognostic indicator of dystocia in
sheep because of elevations in haptoglobin [21]. In com-
parison to cattle, there is considerably less reported on
APP in small ruminants [21], suggesting avenues for ro-
bust research focused in this area. Characterisation of
APP response during infectious disease in sheep and
goats has been identified as an area that would have a
significant knowledge impact [21]. In dogs, it has been
suggested that ceruloplasmin and fibrinogen levels could
have potential in the diagnosis of pregnancy and health
status monitoring of pregnant bitches [68]. The current
school of thought suggests that a single APP should not
be used to monitor a disease process [8,38]. Instead, a
comprehensive index [69] that encompasses both posi-
tive and negative APP as well as those APP that increase
both rapidly and slowly should be employed in order to
correlate better with the inflammatory process [8,62].
This calls for the use of contemporary methodologies to
develop multiple and comprehensive and rapid APP pro-
filing platforms.
Cytokines and chemokines
The physiological effects of LPS are based predomin-
antly on the production and activation of molecular me-
diators such as cytokines [70]. Currently, cytokines are
considered to be the principal mediators coordinating
physiological response to stress stimuli in health or dis-
ease and the immune system [71,72]. They are known
for the recognition, modulation and ultimate response of
an organism to infection by regulation of activation, rep-
lication, chemotaxis and apoptosis of immune cells [73].
The APR is stimulated by the release of cytokines such
as IL-1, IL6 and TNF-α from macrophages and mono-
cytes at the site of inflammation or infection [38,70].
Compared to other species such as humans and mice, it
is still early days for cytokine research in sheep which
has fortunately been enhanced by omics techniques [71].
During infection or LPS stimulation, cytokine genes
are turned on and a ‘storm’ of cytokines is produced.
Under usual circumstances, this storm subsides as the
infection is eliminated and the genes are turned off
[8,73]. However, when cytokines genes remain persist-
ently activated, this can lead to an overactive immune
system and the development of autoimmunity, causing
cell death [73]. Cytokines, therefore, dictate the nature
of the immune response to infection [71]. It should be
acknowledged that intravenous injection of LPS does not
mimic any natural Gram-negative infection and can be
variable. In mice for instance, the initial response to LPS is
pro-inflammatory as TNF-α and IL-1 appear in the blood
long before IL-10 does – and yet there is not much evi-
dence to suggest that this happens in naturally infected
humans [31]. It is, therefore, important to characteriseLPS-induced cytokine expression and profiles in sheep
and document any differences.
Cytokine responses are integral to the survival of the
host, while in some instances, they also seem to drive the
disease process [8]. This dysregulation of the cytokine re-
sponse is present in a number of disease states, including
those that are immune-mediated rather than infectious
[73]. Over-exuberant production of pro-inflammatory cy-
tokines causes death of cells, dysfunction of organs and
death of the organism [20]. This is known as the systemic
inflammatory response syndrome (SIRS) [20].
Each cytokine binds its own receptor and that receptor
has a defined mechanism to its second messenger sys-
tem. Cytokines are not stored. They are expressed as
needed and their expression is tightly controlled. It has
been documented that cytokines peak at different times
during the onset of illness [73]. This makes the use of
cytokines as markers for disease severity difficult [73].
Peaking too long or not peaking at all, or in the wrong
proportions may be responsible for disease states. The
ultimate end product of cytokine production is signal
transduction [20]. Table 2 summarises some known cy-
tokines categorised in families and their action.
Assaying of acute phase proteins
Automated chemistry analysers are commonly used for
basic health assessments for total protein and albumin
[8]. Currently, however, protein electrophoresis (PEP) is
considered as an excellent method for detection for APP
[8]. PEP can provide a more accurate albumin quantita-
tion and visualisation of globulin fractions to monitor
the overall progression of the APR [8]. The downside of
PEP is that it does not enable quantitation of individual
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tors of the acute inflammatory process [8]. It is recom-
mended that baseline parameters for species and strains
should be established by each experimental laboratory
when using PEP or APP tools [8]. Turbidimetric methods
[62], radioimmunoassay (RIA) and ELISA in cattle, for
instance [13], continue to be developed specifically for
rapid determination of CRP [38]. There are some ELISA
kits [68] that have been validated for animal use and are
available to measure specific APP, however most of these
assays lack automation and could prove to be uneconom-
ical [8]. The development of protein microarray method-
ology has been suggested for assaying of APP in pigs
[38]. Considered together, current evidence suggests that
the proteomic approach of APP assay is preferred.
There has been relatively limited use of proteomics to
investigate blood protein patterns in relation to APP as-
says in farm animals [21,62,74]. Proteomic studies in
veterinary medicine, particularly of sheep, remain con-
strained, compared to other species like humans [62].
Proteomic approaches enable large-scale protein ana-
lysis, describing the entire protein component (prote-
ome) from an organism, tissue, cell or biological fluid.
This then provides information on protein expression,
localisation, functions and interactions [62]. There are a
few studies that have described two-dimensional elec-
trophoresis (2-DE) in cattle [40,75-77], horses [78],
sheep [62], swine [79], chicken [80] and companion
small animals [81]. One experimental model used 2-DE
in cattle, followed by Liquid chromatography–mass
spectrometry (LC-MS/MS) for spot identification to de-
termine potential biomarkers of disease outcomes to
predict the occurrence of fatal respiratory disease [82].
Alonso-Fauste et al. [40] used 2-DE coupled with
Matrix-Assisted Laser desorption/Ionisation Time-of-
Flight Mass Spectrometry (MALDI-TOF MS) for prote-
omic characterisation of bovine serum and whey from
healthy and mastitis-affected cattle. They concluded
that existing differences in serum protein patterns be-
tween healthy and acute phase conditions is very useful
in the search for specific biomarkers. Moreover, recent
studies by Chiaradia et al. [62] defined the sheep prote-
ome and identified protein markers that recognise early,
and subclinical disease. Their study concluded that ap-
plying proteomics in putative biomarker discovery for
early diagnosis, as well as monitoring the physiological
and metabolic situations, is critical for ovine welfare
[62]. The downside of investigating the plasma prote-
ome, however, is that few proteins of high abundance
can mask changes in proteins of lower abundance [83].
While it has been suggested that it is necessary to de-
plete major proteins, including high abundance APP
from samples prior to undertaking proteomic investiga-
tions of low abundance proteins [21], other studies [62]have objected to sample pre-treatment such as dealbumi-
nation. Developments in this field suggest that proteomic
investigations are gradually shifting from gel-based 2-DE
to non-gel based studies where LC-MS/MS approaches
are able to identify a wider range of proteins which may
overcome the problem of high abundance proteins [21].
Recently, an approach for proteome analysis has been de-
veloped that combines LC-MS/MS and data extraction
strategy called sequential window acquisition of all theor-
etical fragment-ion spectra (SWATH) or SWATH-MS
[84]. SWATH-MS has been suggested for use in plasma
biomarker discovery studies [85].
The profiles of cytokines can be measured at two
levels, protein or mRNA transcripts using various tech-
niques [72]. In a study on brachycephalic dogs that
assessed concentrations of pro-inflammatory and anti-
inflammatory cytokines in plasma, a specific commer-
cial ELISA kit was used satisfactorily [86]. In another
study, ELISA was used to measure TNF and IFNγ levels
in cell supernatants following LPS stimulation in bovine
peripheral blood mononuclear cells (PBMC) [16]. The
latter study concluded that LPS stimulation alters the
expression of genes encoding epigenetic enzyme in bo-
vine PBMC [16]. Real-time quantitative RT-PCR is the
method commonly used for cytokine gene expression in
tissues and has been used in sheep [72,87-89]. The qRT-
PCR allows for an exponential amplification of the gene
of interest; therefore, overcoming the sensitivity prob-
lems usually encountered with gene expression studies
[72]. Owing to the lack of immunological and biological
assays for the detection of ovine cytokines, Budhia et al.
[72] developed the use of qRT-PCR to detect ovine cyto-
kines. Micro-array methodologies for cytokine assaying
for ruminants have now also been developed [90].
Many potentially novel applications of APP have been
proposed. APP assays could be used as rapid screening
tests for inflammation by providing better sensitivity
when compared to other traditional markers [91]. By re-
placing the currently used subjective assessments, APP
may be useful in defining human endpoints to experi-
mental protocols and also to gauge stress with regard to
animal wellbeing [8]. Studies on APP have shown that
optimum husbandry conditions and isolation of labora-
tory animals minimises contact with potential triggers of
inflammation [54]. Therefore, another potential use of
APP is the assessment of the general health of laboratory
animal colonies and to screen animals before entry into
experimental protocols [8]. Due to the observations of
the dynamic APP response in sheep following vaccin-
ation, it has been suggested that exploitation of this
effect would provide a means to monitor the APP and
innate immune response in the general population with-
out the need for primers such as LPS [21]. Cray et al. [8]
summed it up elegantly that APP are excellent candidates
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monitor health and objectively assess animal wellbeing.
There is undoubtedly a considerable potential for apply-
ing proteomic studies to ovine plasma or serum to fur-
ther understand APR in the pathophysiology of disease,
to benefit the health and welfare of sheep, be it in farm
production or as large animal models of human disease.
Circulating microRNA: the future of biomarkers
The development of functional genomics has created a
considerable interest in discovering circulating bio-
markers that are useful in classifying disease severity and
in gauging therapeutic response to candidate drug inter-
ventions [92]. miRNAs are newly discovered, small non-
coding ribonucleic acids (RNAs) about 22 nucleotides in
length that play critical roles in the regulation of host
genome expression at the post-transcriptional level
[93-95] and are thought to impart stability to biological
systems [96]. Early observations on the lin-4 gene that
codes for short RNAs governing the development of
Caenorhabditis elegans were first reported by Lee et al.
[97] in 1993. In later years, another short RNA let-7 was
identified [98], with a large number of small RNAs being
revealed in 2001 [92], which subsequently opened the
lid to the world of the microRNA biotechnology
[93,99-102]. Recently, Zhang et al. [103] identified and
characterised the miRNA transcriptome of sheep. The
identification of miRNA will promote the study of
miRNA functions and gene regulatory mechanisms [103]
and networks will be subject of many advances in
miRNA biology in the coming years [92].
miRNAs are detectable in a variety of sources, includ-
ing tissues, serum, plasma and other body fluids [104]
and have been reported to be remarkably stable even
under conditions as harsh as boiling, extreme pH, long-
time storage at room temperature and multiple freeze-
thaw cycles [105,106], therefore prompting interest in
this line of research [104,107]. Much as the origin of
cell-free miRNAs in circulation has not been clearly elu-
cidated; they are believed to be released to the extracel-
lular space from damaged or apoptotic cells and are also
actively secreted by cells via exosomes or exocytosis
[108-110]. They are protected against degradation by
being within lipid vesicles or by being associated with
protein or lipoprotein complexes [107]. Furthermore,
miRNA expression is known to be specific in different
tissues [111] and change in different diseases [112,113].
Thus, miRNAs in plasma or serum could be developed
as a novel class of blood-based biomarkers to diagnose
and monitor disease [107,109,114].
The work of Montano [92] observed that there is a
growing recognition that miRNA networks are often as-
sociated with tissue dysfunction and are likely to be a
key source of altered gene expression that distinguisheshealthy tissue from pathological tissue. For example, in
diabetic humans, it has been shown that there is an ap-
parent discordance between proteomic profiles and their
respective miRNA, suggesting a potential role played by
miRNAs [115]. Quite recently, there have been detailed
insights into the function of miRNAs in various disease
states such as liver disease [116], kidney function and
disease [117], cardiac disease [118], therapeutic targets
in cancer [100], biomarkers in lung cancer[119], lung
cancer biology and therapy [120], pulmonary fibrosis
[121], acute lung injury [122] and in understanding im-
munoregulation, inflammation and autoimmune diseases
[93].
Based on the preceding background, it is reasonable to
assume that changes in miRNA profiles occur in sheep
during LPS challenge which may be reflected in plasma.
It is now known that miRNAs are post-transcriptional
regulators of gene expression and are new targets for re-
vealing the molecular mechanism that form traits [103].
There has been a pioneering study as discussed [93,122]
that links miRNAs with innate response based on the
observation that miR-146 and miR-155 are rapidly up-
regulated during LPS stimulation of human monocytic
cells [92]. In addition, there is also mounting evidence
that miRNA have a critical role in immune system
homeostasis [93]. Studies are therefore indicated to char-
acterise the acute phase response by measuring miRNA
expression as potential biomarker candidates in sheep
challenged with LPS. This could in part, help to explain
the differential resilience to endotoxin that has been ob-
served in sheep. It has been proposed that further study
of miRNAs will prove beneficial in the understanding of
physiological and pathological mechanisms in organ-
isms, thus providing a theoretical basis for the diagnosis
and treatment of diseases [103].
Assaying of miRNAs
The detection and quantification of miRNAs in plasma
and serum samples is an area that continues to grow
[109,123-125]. In brief, the methods commonly used
quantify miRNAs are quantitative reverse-transcriptase
polymerase chain reaction (qRT-PCR) profiling and
micro-array technology [107]. One study [123] revealed
that vesicle-associated plasma miRNA was in the minor-
ity, whereas potentially, up to 90% of miRNAs in circula-
tion are present in the non-membrane bound form. The
relative ease by which miRNAs can be detected in a qRT-
PCR and microarrays makes it immensely motivating to
study circulating miRNAs as clinical biomarkers in a
sheep model following an LPS challenge. Circulating
miRNAs are known to fulfil a number of criteria that
an ideal biomarker has as discussed and summarised
by Creemers et al. [107]. Most importantly, circulating
miRNAs can be accessed by non-invasive methods.
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circulating miRNAs are quite tissue- or pathology-
specific for given tissue pathologies, and their sequences
are evolutionarily conserved [107], they may also have
the potential to provide the much-needed intermediate
endpoints for animal experimental studies. It would also
be interesting to determine whether candidate miRNA
profiles in sheep correlate with some of the published
levels of plasma proteins and cytokines.
There are challenges associated with the detection of
circulating miRNAs. There are low numbers of total
RNA molecules in blood fluid compartment, which
raises concerns with measuring the concentration and
quality of isolated RNA [107]. It has been proposed that
it is important to precisely normalise [125] detected
miRNA values for variances based on the amount of
starting material and miRNA extraction, by seeking a
“housekeeping” circulating RNA, for instance [107].
Plasma or serum volume has been proposed as the best
parameter by which to standardise the amount of input
miRNA [126]. Similarly, the number of molecules per
volume of plasma or serum is also used as a standard to
evaluate blood levels of other molecules [107]. In
addition to normalisation of qRT-PCR data, an appropri-
ate control is a requirement for diagnostic studies [125].
Together, these observations mean that studies are
indicated to characterise the different normalisation
methods and find the best ways to reproducibly measure
miRNA in plasma [107] especially in data-scarce and
equally important large animal species such as sheep.
Next-generation sequencing (NGS) technologies are
regarded as the next step to be used for discovering
novel miRNAs as they are not biased by qRT-PCR and
microarray platforms [127]. Combining multiple miR-
NAs into a miRNA profile may provide greater accuracy
than a single miRNA [107]. With only approximately
100 miRNAs characterised in human plasma thus far,
profiling all the miRNA may provide a comprehensive
analysis of pathologies in multiple organs, even in sheep.
With respect to sheep, no real-time or NGS has been
performed to characterise circulating miRNA expression
in response to LPS challenge, therefore calling for re-
search in this area.
E - Perspectives
Genomic tools and approaches in sheep have lagged be-
hind and have been dwarfed by more influential, and yet
equally significant farm animals such as cattle if looked
at from a functional genetics point of view [128]. Height-
ened interest in the understanding of sheep has led to
new evidence that supports their relevance and suitabil-
ity as experimental models for understanding critical ill-
nesses in humans as recently reviewed in related studies
[129]. Improved production traits in meat, milk and finewool currently constitute the predominant spectrum of
the phenotypes of modern breeds of sheep at the ex-
pense of original strains [7]. It is also now known that
conventional genetic improvement programmes aimed
at increasing profitability have found it difficult to in-
corporate disease resistance in multi-trait breeding ob-
jectives [128]. Previous studies have largely been on
European-derived breeds of sheep which prompted the
recent landmark study on diverse breeds across the
world to better understand the genetic composition and
history of sheep [7]. The study genotyped the global di-
versity of sheep using the ovine SNP50 Bead chip tech-
nology and deduced that, among other traits, the most
robust selection signal occurred in response to breeding
for the absence of horns [7]. Could the focus on selective
breeding for polled sheep have led to the propagation of
more disease-prone sheep?
Conclusions
The current review has established a framework for un-
derstanding selective susceptibility to infection with
reference to endotoxin through a proteogenomic ap-
proach. The identification of unique signature and
disease-related APP and miRNAs provides the founda-
tion for the next phase of studies: 1) to mechanistically
understand the pathogenic contribution of endotoxin-
related APP and miRNAs, 2) to determine the cause and
mechanism underlying APP and miRNA dysregulation
in experimental LPS challenge and stress for example
during transportation, and 3) to ultimately develop novel
APP and miRNA-based biomarker assay with potentially
unrivalled specificity and sensitivity. To address these
central questions, a relevant large animal model of infec-
tion is instrumental. It is anticipated that, in future, to
treat infectious or stress-related diseases, novel effective
APP and miRNA-based gene therapies will be developed
to replace the traditional currently available therapies,
which are sometimes unsatisfactory or have undesirable
side effects.
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